BETHESDA, Md., July 18, 2017 /PRNewswire/ -- PepVax, Inc., an early stage biotechnology company developing an immunotherapy treatment for triple-negative breast cancer (TNBC), today announced several new milestones and upcoming events that demonstrate the company's continued growth.
PepVax has successfully completed early toxicology studies for its lead candidate, PVX-009. The goal of this study was to verify previous toxicology results and also determine the best combination and dosages to move towards efficacy studies.
In May, PepVax was chosen to present along with other promising startups for the MedCity INVEST Pitch Perfect contest in Chicago. These companies were selected by an elite group of venture capitalists and industry leaders because of their innovative approaches and/or research being developed to solve some of the biggest problems in healthcare. In June, PepVax was also selected to present at the International Cancer Cluster Symposium in San Diego as part of the BIO Convention. The companies were chosen across both North America and Europe to showcase their technologies for finding better treatments for various cancers.
Mahesh Narayanan, Chief Executive Officer, will present at MedCity CONVERGE conference on Monday, July 31st in Philadelphia. PepVax's presentation will focus on its unique approach to cancer immunotherapy and the recent animal trial results. The animal trials followed completion of positive in-vitro trials that targeted a specific protein, MAGE A, to find a better treatment for TNBC.
In September, PepVax will be completing a two-week immersion program in Lausanne, Switzerland designed to help entrepreneurs grow their business in Switzerland and Europe. The goals of the program are to initiate or strengthen various collaborations with European institutions and connect the company to extensive resources and business networks in Europe. With new partnerships involving various companies in Europe, PepVax plans to conduct its first in vivo efficacy studies in Q3 2017.
About PepVax, Inc.
PepVax, Inc. was founded in 2013 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.pepvax.co